Form 4 for ABUS Arbutus Biopharma Corp
Accepted 2025-02-05 00:00:00 ET · period of report 2025-02-04 · accession 0001447028-25-000037 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-02-05 | 2025-02-04 | ABUS | Naftzger J. Christopher | GC, CCO | S - Sale | $3.28 | -11.3K | 86.2K | -12% | -$37.2K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Shares | 2025-02-04 | S | D | 11,333 | $3.28 | 86,244 | D | — | — | (F2) Includes 1,214 and 1,263 shares acquired under the Arbutus Biopharma Corporation 2020 Employee Stock Purchase Plan on February 29, 2024 and August 30, 2024, respectively. |